Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1603-1 and NVP-1603-2 in Healthy Male Volunteers

Trial Profile

Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1603-1 and NVP-1603-2 in Healthy Male Volunteers

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs NVP 1603 (Primary)
  • Indications Pain
  • Focus Pharmacokinetics
  • Sponsors Navipharm
  • Most Recent Events

    • 08 Mar 2018 Planned End Date changed from 31 May 2018 to 31 Oct 2018.
    • 08 Mar 2018 Planned primary completion date changed from 28 Feb 2018 to 28 Oct 2018.
    • 08 Mar 2018 Planned initiation date changed from 1 Jan 2018 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top